Eisai’s next mid-term business plan, due out early March, will embrace a new development in its generic operations, Hideki Hayashi, representative corporate officer in charge of corporate planning and strategy, said on February 2.

The major Japanese drug maker is “actively considering a new development” in the operations run by its generic unit Elmed Eisai, Mr Hayashi said, answering questions from analysts at an earnings conference for April-December 2015. It will be incorporated in the company’s new business plan, which will be announced on March 3-4, he said. “We won’t immediately split off the generic business,” he noted.